| Authorised form of name | Abell; Christopher (1957 - 2020) |
| Dates | 1957 - 2020 |
| Nationality | British |
| Place of birth | Fulford, New York, United States, North and Central America |
| Date of birth | 11/11/1957 |
| Date of death | 26/10/2020 |
| Occupation | Biological chemist |
| Research field | Chemistry |
| Biochemistry |
| Molecular medicine |
| Pharmaceuticals |
| Activity | Education:
Selby Grammar School (1969-1976); St. John's College, University of Cambridge, BA (Cantab) in Chemistry (1976-1979); University of Cambridge, PhD on Polyketide biosynthesis (1979-1982)
Career:
S.E.R.C. Overseas Postdoctoral Fellowship with Professor D. E. Cane studying enzymology of terpene biosynthesis, Brown University, Providence, Rhode Island, United States of America (1982-1983); Research Fellowship, King's College, Cambridge (1983-1986); University of Cambridge, University Demonstrator in Chemistry (1984-1988); University Lecturer in Chemistry (1988-1999); Reader in Chemical Biology (1999-2002); Professor of Biological Chemistry (2002-2020); Director of Postdoctoral Affairs (2013-2015); ProViceChancellor Research (2016-2020); Hickinbottom Fellowship, Royal Society of Chemistry (1991-1992); Iberdrola Visiting Professor, Santiago de Compostela (1999-2000); Co-founder and Director, Astex Technology (1999-2000); Erskine Fellowship, Canterbury University, Christchurch (2000); Co-founder, Akubio (2002); David Craig Visiting Professor, Australian National University, Canberra (2003); Director, Cambridge Enterprise (2006-2011); Novartis Lecturer, Massachusetts Institute of Technology (2008); Visiting Professor, Université Paul Sabatier, Toulouse (2008-2009); BIC International Fellow, University of Canterbury, Christchurch, New Zealand (2011); Co-founder and Director, Sphere Fluidics (2010-2015); Co-founder, Aqdot (2013)
Memberships:
FMedSci (2012)
Medals/Awards:
Yamada Science Foundation Award 1992; ICI Prize in Organic Chemistry 1992 |
| Membership category | Fellow |
| Date of election | 28/04/2016 |
| Age at election | 58 |
| RSActivity | Committee and panels:
Emerging Technologies Working Group (2017-2020) |
| PublishedWorks | https://www.worldcat.org/identities/lccn-n85146971 |
| OtherInfo | Chris was the Professor of Biological Chemistry at the University of Cambridge. A major focus of his highly interdisciplinary research was to understand the mechanisms of key enzymes, and develop approaches to their inhibition. He was a pioneer in the development of fragment-based approaches to drug discovery, and co-founder of Astex (1999), a world leading company in this area. Fragment-based approaches are now adopted throughout the pharmaceutical industry and in many academic laboratories. Chris used these structural biology driven approaches to develop treatments for tuberculosis and cancer. |
| Source | Sources:
Wikipedia, https://en.wikipedia.org/wiki/Chris_Abell(accessed 11 November 2020)
Royal Society profile, https://royalsociety.org/people/christopher-abell-12842/ (accessed 11 November 2020)
Book of rememberance, https://www.remembr.com/professor.chris.abell (accessed 11 November 2020)
References:
https://www.cam.ac.uk/research/news/professor-chris-abell-frs-fmedsci-1957-2020 (obituary, accessed 11 November 2020) |
| Virtual International Authority File | http://viaf.org/viaf/39980681 |
| Code | NA10015 |